AU2016205030B2 - Restoring physiology in iron-deficient organisms using small molecules - Google Patents

Restoring physiology in iron-deficient organisms using small molecules Download PDF

Info

Publication number
AU2016205030B2
AU2016205030B2 AU2016205030A AU2016205030A AU2016205030B2 AU 2016205030 B2 AU2016205030 B2 AU 2016205030B2 AU 2016205030 A AU2016205030 A AU 2016205030A AU 2016205030 A AU2016205030 A AU 2016205030A AU 2016205030 B2 AU2016205030 B2 AU 2016205030B2
Authority
AU
Australia
Prior art keywords
iron
hinokitiol
small molecule
panel
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016205030A
Other languages
English (en)
Other versions
AU2016205030A1 (en
Inventor
Martin D. Burke
Anthony S. Grillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Publication of AU2016205030A1 publication Critical patent/AU2016205030A1/en
Application granted granted Critical
Publication of AU2016205030B2 publication Critical patent/AU2016205030B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2016205030A 2015-01-09 2016-01-11 Restoring physiology in iron-deficient organisms using small molecules Active AU2016205030B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562101706P 2015-01-09 2015-01-09
US62/101,706 2015-01-09
US201562251964P 2015-11-06 2015-11-06
US62/251,964 2015-11-06
PCT/US2016/012855 WO2016112381A1 (en) 2015-01-09 2016-01-11 Restoring physiology in iron-deficient organisms using small molecules

Publications (2)

Publication Number Publication Date
AU2016205030A1 AU2016205030A1 (en) 2017-08-03
AU2016205030B2 true AU2016205030B2 (en) 2021-04-01

Family

ID=56356533

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016205030A Active AU2016205030B2 (en) 2015-01-09 2016-01-11 Restoring physiology in iron-deficient organisms using small molecules

Country Status (5)

Country Link
US (2) US11517540B2 (https=)
EP (1) EP3242723B1 (https=)
JP (1) JP6725515B2 (https=)
AU (1) AU2016205030B2 (https=)
WO (1) WO2016112381A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700021676A1 (it) * 2017-02-28 2018-08-28 Carlo Angelo Ghisalberti Composizioni e sistemi di estrazione del ferro non-eme dalla dieta per uso nell’anemia sideropenica e carenze marziali
WO2019191270A1 (en) * 2018-03-27 2019-10-03 The Board Of Trustees Of The University Of Illinois Restoration of transmembrane copper transport
AU2019252933B2 (en) * 2018-04-13 2025-09-04 The Board Of Trustees Of The University Of Illinois Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
EP4045025A4 (en) * 2019-10-16 2023-11-22 Kinesid Therapeutics, Inc. TROPOLONE DERIVATIVES AND THEIR TAUTOMERS FOR IRON REGULATION IN ANIMALS
US20230406803A1 (en) * 2019-10-16 2023-12-21 Kinesid Therapeutics, Inc Tropolone derivatives and tautomers thereof for iron regulation in animals

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163849A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Compositions and dosage forms for enhanced absorption of iron
US20050176827A1 (en) * 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
US20060128805A1 (en) * 2004-11-19 2006-06-15 Shah Sudhir V Methods of treating erythropoietin-resistance
WO2008143869A1 (en) * 2007-05-14 2008-11-27 Toucan Capital Corporation Method of indentifying compounds that modulate regulation of iron response elements
WO2009138761A1 (en) * 2008-05-15 2009-11-19 Vitra Pharmaceuticals Limited Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections
WO2010005851A1 (en) * 2008-07-08 2010-01-14 Xenon Pharmaceuticals Inc. Combination therapy for treating iron disorders
US20120135091A1 (en) * 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
WO2014152006A2 (en) * 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0315018A (pt) 2002-10-04 2005-09-06 Hoffmann La Roche Uso de anticorpos dos receptores de il-2 para prevenir toxicidade associada à terapia antimicótica com anfotericina b
MA33090B1 (fr) 2009-01-26 2012-03-01 Michael Spino Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer
US8372857B2 (en) 2009-06-30 2013-02-12 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
GB201101370D0 (en) 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
CN104105482B (zh) 2011-10-12 2017-10-24 思佰益药业股份有限公司 红细胞生成素产生促进剂
TW201400472A (zh) 2012-03-30 2014-01-01 Daiichi Sankyo Co Ltd ５－羥基嘧啶－４－甲醯胺衍生物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176827A1 (en) * 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
US20050163849A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Compositions and dosage forms for enhanced absorption of iron
US20060128805A1 (en) * 2004-11-19 2006-06-15 Shah Sudhir V Methods of treating erythropoietin-resistance
US20120135091A1 (en) * 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
WO2008143869A1 (en) * 2007-05-14 2008-11-27 Toucan Capital Corporation Method of indentifying compounds that modulate regulation of iron response elements
WO2009138761A1 (en) * 2008-05-15 2009-11-19 Vitra Pharmaceuticals Limited Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections
WO2010005851A1 (en) * 2008-07-08 2010-01-14 Xenon Pharmaceuticals Inc. Combination therapy for treating iron disorders
WO2014152006A2 (en) * 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GASCHE CHRISTOPH ET AL, (2014) INFLAMMATORY BOWEL DISEASES, vol. 21 pages 579 - 588 *
Y. Ido ET AL, (1999-02-01), pages 63 - 73, URL: https://onlinelibrary.wiley.com/doi/epdf/10.1046/j.1365-2184.1999.3210063.x, *

Also Published As

Publication number Publication date
JP6725515B2 (ja) 2020-07-22
US20180263926A1 (en) 2018-09-20
EP3242723A1 (en) 2017-11-15
EP3242723A4 (en) 2018-07-25
EP3242723B1 (en) 2021-10-06
AU2016205030A1 (en) 2017-08-03
US11517540B2 (en) 2022-12-06
JP2018504392A (ja) 2018-02-15
WO2016112381A1 (en) 2016-07-14
US20230293452A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US20230293452A1 (en) Restoring physiology in iron-deficient organisms using small molecules
US20220339121A1 (en) Novel 2,4-Dinitrophenol Formulations and Methods Using Same
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
EP3485882A1 (en) Compositions for the treatment of pervasive development disorders
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
JP2018076332A (ja) （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法
TW202327589A (zh) 肝病之組合療法
US20250114312A1 (en) Treatment of copper disorders
US20250262267A1 (en) Curcumin compositions and methods of use as an nk3 antagonist
JP7041961B2 (ja) ヒト嚢胞性線維症肺上皮における気道表面の生理機能の小分子介在性回復
US20210030725A1 (en) Restoration of transmembrane copper transport
CN101675932B (zh) 一种防治肌萎缩侧索硬化的组合物
US11213494B2 (en) Compositions and methods for the treatment of pervasive development disorders
US20230142111A1 (en) Compositions and methods for the treatment of pervasive development disorders
WO2026080585A1 (en) Treatment of retinal degeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)